CD4 and myeloid sarcoma: Later, Horellou et al. stimulated PBMCs with recombinant full-length MOG protein (rhMOG) and observed increased IL17+ CD4 T cells in non-relapsing (monophasic) MOGAD patients upon rhMOG stimulation, but not in relapsing MOGAD or MS (124).